title: A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
authors.affiliation: Head and Neck Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. furym@mskcc.org
authors.forename: Matthew G
authors.initials: MG
authors.lastname: Fury
authors.forename: Sofia
authors.initials: S
authors.lastname: Haque
authors.forename: Hilda
authors.initials: H
authors.lastname: Stambuk
authors.forename: Ronglai
authors.initials: R
authors.lastname: Shen
authors.forename: Diane
authors.initials: D
authors.lastname: Carlson
authors.forename: David
authors.initials: D
authors.lastname: Pfister